Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun-Yi Wu

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Journal of Hepatocellular Carcinoma|December 2, 2024
Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective StudyDe-Yi Liu, Yi-Nan Li, Jia-Yi Wu, et al.
Annals of Surgical Oncology|April 30, 2021
Long-Term Outcomes of Anatomic Versus Nonanatomic Resection in Hepatocellular Carcinoma Patients with Bile Duct Tumor Thrombus: A Propensity Score Matching AnalysisJia-Yi Wu, Ju-Xian Sun, Yan-Nan Bai, et al.
Diagnostics (Basel, Switzerland)|May 1, 2025
Systematic Analysis of Multiple Imaging Modalities in Infants Diagnosed with Mucopolysaccharidosis by Newborn ScreeningChung-Lin Lee, Szu-Wen Chang, Hung-Hsiang Fang, et al.
Journal of Hepatocellular Carcinoma|December 11, 2023
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?Jia-Yi Wu, Jun-Yi Wu, De-Yi Liu, et al.
Journal of Hepatocellular Carcinoma|October 18, 2023
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective StudyShu-Qun Li, Jun-Yi Wu, Jia-Yi Wu, et al.
Liver Cancer|October 22, 2024
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion SurgeryZhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, et al.
Liver Cancer|August 20, 2025
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple TherapyJun-Yi Wu, Zhen-Xin Zeng, Yi-Nan Li, et al.
Frontiers in Oncology|December 19, 2023
Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: a multicenter studyLi-Ming Huang, Zhen-Xin Zeng, Jun-Yi Wu, et al.
Journal of Hepatocellular Carcinoma|September 30, 2024
Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching StudyZhong-Tai Lin, Shao-Ming Wei, Jun-Yi Wu, et al.
Liver Cancer|September 28, 2023
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective StudyJia-Yi Wu, Zhi-Bo Zhang, Jian-Yin Zhou, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Journal of Hepatocellular Carcinoma|December 2, 2024
Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective StudyDe-Yi Liu, Yi-Nan Li, Jia-Yi Wu, et al.
Annals of Surgical Oncology|April 30, 2021
Long-Term Outcomes of Anatomic Versus Nonanatomic Resection in Hepatocellular Carcinoma Patients with Bile Duct Tumor Thrombus: A Propensity Score Matching AnalysisJia-Yi Wu, Ju-Xian Sun, Yan-Nan Bai, et al.
Diagnostics (Basel, Switzerland)|May 1, 2025
Systematic Analysis of Multiple Imaging Modalities in Infants Diagnosed with Mucopolysaccharidosis by Newborn ScreeningChung-Lin Lee, Szu-Wen Chang, Hung-Hsiang Fang, et al.
Journal of Hepatocellular Carcinoma|December 11, 2023
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?Jia-Yi Wu, Jun-Yi Wu, De-Yi Liu, et al.
Journal of Hepatocellular Carcinoma|October 18, 2023
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective StudyShu-Qun Li, Jun-Yi Wu, Jia-Yi Wu, et al.
Liver Cancer|October 22, 2024
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion SurgeryZhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, et al.
Liver Cancer|August 20, 2025
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple TherapyJun-Yi Wu, Zhen-Xin Zeng, Yi-Nan Li, et al.
Frontiers in Oncology|December 19, 2023
Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: a multicenter studyLi-Ming Huang, Zhen-Xin Zeng, Jun-Yi Wu, et al.
Journal of Hepatocellular Carcinoma|September 30, 2024
Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching StudyZhong-Tai Lin, Shao-Ming Wei, Jun-Yi Wu, et al.
Liver Cancer|September 28, 2023
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective StudyJia-Yi Wu, Zhi-Bo Zhang, Jian-Yin Zhou, et al.
Pageof 7